113 related articles for article (PubMed ID: 38799768)
1. A Targetable Receptor Tyrosine Kinase in Metastatic Pheochromocytoma and Paraganglioma: A Future Journey for Anlotinib?
Alkaissi H; Pacak K
J Endocr Soc; 2024 May; 8(7):bvae092. PubMed ID: 38799768
[No Abstract] [Full Text] [Related]
2. Anlotinib for Metastatic Progressed Pheochromocytoma and Paraganglioma: A Retrospective Study of Real-World Data.
Tian R; Yao X; Song J; Wang J; Fu J; Shi L; Yu F; Zhang P; Zhang C; Ni Y; Wang F
J Endocr Soc; 2024 Apr; 8(6):bvae061. PubMed ID: 38650712
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.
Zhou AP; Bai Y; Song Y; Luo H; Ren XB; Wang X; Shi B; Fu C; Cheng Y; Liu J; Qin S; Li J; Li H; Bai X; Ye D; Wang J; Ma J
Oncologist; 2019 Aug; 24(8):e702-e708. PubMed ID: 30902918
[TBL] [Abstract][Full Text] [Related]
4. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development.
Shen G; Zheng F; Ren D; Du F; Dong Q; Wang Z; Zhao F; Ahmad R; Zhao J
J Hematol Oncol; 2018 Sep; 11(1):120. PubMed ID: 30231931
[TBL] [Abstract][Full Text] [Related]
5. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
[TBL] [Abstract][Full Text] [Related]
6. Targeted Therapies in Pheochromocytoma and Paraganglioma.
Wang K; Crona J; Beuschlein F; Grossman AB; Pacak K; Nölting S
J Clin Endocrinol Metab; 2022 Nov; 107(11):2963-2972. PubMed ID: 35973976
[TBL] [Abstract][Full Text] [Related]
7. Malignant pheochromocytoma and paraganglioma: management options.
Corssmit EPM; Snel M; Kapiteijn E
Curr Opin Oncol; 2020 Jan; 32(1):20-26. PubMed ID: 31599769
[TBL] [Abstract][Full Text] [Related]
8. [Antiangiogenic therapy of malignant pheochromocytoma and paraganglioma with the view to the recent scientific developments].
Kukla U; Łabuzek K; Chronowska J; Bobrzyk M; Madej P; Okopień B
Pol Merkur Lekarski; 2015 Apr; 38(226):191-5. PubMed ID: 25938384
[TBL] [Abstract][Full Text] [Related]
9. Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study.
Fischer A; Kloos S; Remde H; Dischinger U; Pamporaki C; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Bechmann N; Hantel C; Mohr H; Pellegata NS; Bornstein SR; Kroiss M; Auernhammer CJ; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
Eur J Endocrinol; 2023 Nov; 189(5):546-565. PubMed ID: 37949483
[TBL] [Abstract][Full Text] [Related]
10. Combined Treatment With 131I-MIBG and Sunitinib Induces Remission in a Patient With Metastatic Paraganglioma Due to Hereditary Paraganglioma-Pheochromocytoma Syndrome From an SDHB Mutation.
Makis W; McCann K; McEwan AJ; Sawyer MB
Clin Nucl Med; 2016 Mar; 41(3):204-6. PubMed ID: 26359568
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
Cassol CA; Winer D; Liu W; Guo M; Ezzat S; Asa SL
Mod Pathol; 2014 Aug; 27(8):1050-62. PubMed ID: 24390213
[TBL] [Abstract][Full Text] [Related]
12. Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial.
Ma J; Song Y; Shou J; Bai Y; Li H; Xie X; Luo H; Ren X; Liu J; Ye D; Bai X; Fu C; Qin S; Wang J; Zhou AP
Front Oncol; 2020; 10():664. PubMed ID: 32457838
[No Abstract] [Full Text] [Related]
13. Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma.
Carrasquillo JA; Chen CC; Jha A; Pacak K; Pryma DA; Lin FI
J Nucl Med; 2021 Sep; 62(9):1192-1199. PubMed ID: 34475242
[TBL] [Abstract][Full Text] [Related]
14. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations.
King KS; Prodanov T; Kantorovich V; Fojo T; Hewitt JK; Zacharin M; Wesley R; Lodish M; Raygada M; Gimenez-Roqueplo AP; McCormack S; Eisenhofer G; Milosevic D; Kebebew E; Stratakis CA; Pacak K
J Clin Oncol; 2011 Nov; 29(31):4137-42. PubMed ID: 21969497
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China.
Lin J; Fang Q; Zheng X
PLoS One; 2023; 18(2):e0281402. PubMed ID: 36749752
[TBL] [Abstract][Full Text] [Related]
16. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma.
Koh JM; Ahn SH; Kim H; Kim BJ; Sung TY; Kim YH; Hong SJ; Song DE; Lee SH
PLoS One; 2017; 12(11):e0187398. PubMed ID: 29117221
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.
O'Kane GM; Ezzat S; Joshua AM; Bourdeau I; Leibowitz-Amit R; Olney HJ; Krzyzanowska M; Reuther D; Chin S; Wang L; Brooks K; Hansen AR; Asa SL; Knox JJ
Br J Cancer; 2019 Jun; 120(12):1113-1119. PubMed ID: 31105270
[TBL] [Abstract][Full Text] [Related]
18. Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study.
Zhou Y; Zeng C; Sun X; Zhang J; Qu H; Zhang X; Zhou Y; Liu Z; Wu X; Wu X; Jiao X; Shen L; Zhou Y; Wang Y; Li J
Oncologist; 2023 Apr; 28(4):e191-e197. PubMed ID: 36779523
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors.
Toledo R; Jimenez C
F1000Res; 2018; 7():. PubMed ID: 30109021
[TBL] [Abstract][Full Text] [Related]
20. Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted?
Ellis RJ; Patel D; Prodanov T; Sadowski S; Nilubol N; Adams K; Steinberg SM; Pacak K; Kebebew E
J Am Coll Surg; 2013 Sep; 217(3):489-96. PubMed ID: 23891076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
